Publications by authors named "T Sohda"
Article Synopsis
- This study compares the effectiveness and safety of Atezolizumab plus Bevacizumab (ATEZO/BEVA) versus Lenvatinib (LEN) as first-line treatments for hepatocellular carcinoma (HCC).
- A total of 810 patients were analyzed, and after matching for comparable characteristics, the results showed no significant difference in objective response rates (44.8% for ATEZO/BEVA vs. 46.7% for LEN), but ATEZO/BEVA had better progression-free survival and overall survival rates.
- ATEZO/BEVA also had lower rates of severe side effects like appetite loss and fatigue, but a higher rate of severe bleeding, and showed a better conversion
Improvements in the hepatocellular carcinoma (HCC) recurrence rate and survival have been frequently reported following virus eradication after hepatitis C virus (HCV)-related HCC cure. However, the efficacy of direct-acting antiviral (DAA) therapy in patients who included those with advanced HCC and decreased hepatic functional reserve is unknown. A comparative examination was retrospectively conducted of 141 patients with hepatitis C who started DAA therapy within 1 year after undergoing curative HCC treatment and showed a sustained viral response (SVR) and 327 patients who underwent curative treatment for HCV-related HCC and did not subsequently receive antiviral therapy.
View Article and Find Full Text PDFArticle Synopsis
- The study analyzed 20,547 cases of hepatocellular carcinoma (HCC) over 24 years, focusing on trends in sex, age, and disease causes, divided into four 6-year periods.
- The data revealed that a significant majority (68.2%) of HCC patients were male, with the average age of newly-diagnosed patients increasing over time, particularly in the elderly population.
- HCC cases associated with hepatitis C virus (HCV) declined, while cases with non-B viral causes and hepatitis B virus (HBV) infections rose, indicating a shift in the epidemiological profile of HCC patients.
Objective Hepatitis C virus (HCV) eradication is associated with decreased serum ferritin and increased serum low-density lipoprotein-cholesterol (LDL-C) levels, although the mechanisms underlying these changes remain unclear. This study aimed to identify the mechanisms underlying the changes in iron and lipid metabolism after HCV eradication. Methods We retrospectively investigated iron and lipid metabolism changes in 22 patients with chronic hepatitis or compensated liver cirrhosis with HCV genotype 1b infection after HCV eradication.
View Article and Find Full Text PDFBackground: Lenvatinib (LEN) has been approved for patients with unresectable hepatocellular carcinoma (u-HCC) since March 2018 in Japan. We performed a retrospective nationwide multicenter study to clarify the clinical characteristics of LEN in real-world practice.
Methods: A total of 343 u-HCC patients who received LEN from March 2018 to May 2020 at 23 sites in Japan were registered.